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Abstract: A group of 36 biphenyl derivatives structurally related to honokiol were 
synthesised by means of Suzuki coupling reactions. Their cytotoxicities were evaluated 
and compared to that of honokiol. Some of the compounds were then evaluated for their 
ability to downregulate the secretion of the VEGF protein and the expression of the VEGF, 
hTERT and c-Myc genes, the two latter involved in the activation of telomerase in tumoral 
cells. Some of the synthetized derivatives showed promising pharmacological features as 
they exhibited IC50 values in low micromolar range, good therapeutic margins and a 
multiple mode of action on tumor cells based on the inhibition of VEGF and, at the same 
time, of the expression of genes related to the activation of telomerase. 
Keywords: honokiol analogues, angiogenesis, gene regulation, VEGF, telomerase, 
hTERT, c-Myc 
 
Molecules containing biaryl moieties are relatively common within natural products. For their 
preparation, Nature has developed an ample array of biosynthetic strategies (1). A number of these 
biaryl natural products belong to the biogenetic class of lignans (2). Honokiol (Figure 1), has aroused a 
great degree of interest because of their various pharmacological properties. This product and many 
derivatives thereof, both of natural and synthetic origin, have been reported to display anti-oxidative, 
anti-inflammatory, anti-tumor, anti-diabetic, anti-microbial, anti-neurodegenerative, anti-depressant, 
pain control, gastrointestinal, cardiovascular and liver protective properties, among others (3,4). 
We have been investigating a range of analogues of natural products (5) for their cytotoxicity and 
potential value in anticancer therapy (6). The latter feature may be related to the ability of the 
compounds to disrupt microtubule dynamics (7), to inhibit the angiogenesis process (8) or to inhibit 
the expression of genes related to telomerase activation (9) among other alternative mechanisms. 
Thanks to the intense studies on genes that mediate cancer progression and therapeutic resistance, 
many gene targets that regulate apoptosis, proliferation and cell signaling have been identified. 
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Multiple cumulative genetic and/or epigenetic changes are needed to cause cancer. Molecules that can 
inhibit expression of such genes are powerful tools in cancer research (10). In this sense, 
methodologies focused on sequence-specific gene suppression strategies involving antisense 
oligonucleotides and ribozymes or else involving gene silencing using RNA interference (RNAi) have 
been developed (11). However, their adaptation as broadly applicable functional genomic and 
therapeutic tools has proven difficult because of problems regarding stability and poor efficiency of 
delivery. 
  
Figure 1. Structure of honokiol 
Many experiments have shown that targeting a single gene can inhibit the growth and proliferation 
of tumor cells (12). However, interference targeting a single gene has limitations in the prevention and 
treatment of cancer as it is known that tumorigenesis results in many cases from multiple gene 
mutation. Therefore, therapies targeting multiple genes may have better effects on malignant tumors. 
In most solid tumors, angiogenesis is an important process for tumor growth and metastasis (13). 
Many different mediators are involved in this process, including VEGF, which has been shown to play 
a critical role in pathological angiogenesis (14). VEGF levels in serum are tightly associated to a more 
aggressive disease state and may serve as a marker to evaluate diagnosis. Blocking VEGF expression 
can inhibit tumor growth and prevent metastasis (15). 
Most cancer cells also exhibit telomerase activity. The latter mantains the length of the telomeres, 
thus preserving genomic stability (16). Telomerase is a ribonucleoprotein composed of two main 
subunits which, in the case of human beings, are called human telomerase RNA (hTR) and human 
telomerase protein (hTERT). Many studies have demonstrated that interference in the expression of the 
hTERT gene can efficiently inhibit the growth and tumorigenicity of cancer cells (17), as the hTERT 
gene is a rate-limiting factor in telomerase synthesis and activity. Equally important is the c-Myc gene, 
which has been found to be amplified in various types of human cancers such as, for example, lung 
carcinoma (18), breast carcinoma (19) and colon carcinoma (20). The result of the expression of this 
gene, the c-Myc protein, is a transcriptional factor with an important role in cell proliferation, 
differentiation, invasion and adhesion of tumor cells (21). It is also involved in the activation of hTERT 
gene transcription (17). 
Since on one hand tumoral cell secretion of VEGF is an important factor in metastasis and, on the 
other hand, telomerase is responsible for the immortality of tumoral cells, we consider that the 
potential multiple ability (22) of some compounds to perturb microtubule dynamics and, at the same 
time, to inhibit VEGF secretion by tumoral cells and the expression of the VEGF, hTERT and c-Myc 
genes is a goal worth pursuing. 
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As the natural biphenyl derivative honokiol displays valuable anticancer activity, we decided to 
prepare a number of synthetic biphenyl derivatives, such as 1-36 (Figure 2), and to investigate their 
behavior in each of the aforementioned three types of biological activities. In fact, many of these 
compounds can be viewed as analogues of honokiol that differ in the relative positions of the C-allyl 
and OH groups. In some cases, hydroxyl functions have been replaced by OMe groups. The C-allyl 
groups were introduced by means of Claisen rearrangement (23) in precursors having O-allyl groups. 
The latter have also been used in the biological evaluations. It is worth noting that the biphenyl moiety 
present in all compounds can be considered a privileged structure (24) that may prove useful in the 
development of lead compounds. Indeed, small molecules have always aroused interest in cancer 
therapy (25). 
 
 
Figure 2. Structure of biphenyl derivatives investigated in this study. 
 
Chemistry 
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The starting materials for the synthesis of compounds 1-36 were hydroxylated biphenyl derivatives 
prepared by means of palladium-catalyzed Suzuki coupling (26). The phenolic functions were then O-
allylated and the resulting O-allyl derivatives subjected to Claisen rearrangement (Scheme 1) under 
Lewis acid catalysis (23). Compounds with O-allyl groups ortho or para to the other benzene ring (1, 
2, 5, 8-11, 14-17) gave single compounds in the Claisen rearrangements. Those having O-allyl groups 
meta to the other benzene ring (3, 4, 6, 7, 12, 13, 18 and 36) gave mixtures of regioisomeric 
rearrangement products. In the case of compounds 6, 12 and 18, the mixtures could be 
chromatographically resolved into their individual components. These were then subjected to 
biological evaluation. However, compounds 3, 4, 7, 13 and 36 gave mixtures which could not be 
separated into pure components. No biological evaluation of such mixtures was carried out. 
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Scheme 1. Synthesis and structures of biphenyl derivatives. 
 
Methods and Materials 
Chemistry 
Conditions for O-allylations (27) 
A mixture of the appropriate phenol (10 mmol) and K2CO3 (2.07 g, 15 mmol) was dissolved in 
acetone (15 mL). Allyl bromide (1.1 mL, ca. 12.5 mmol) was then added dropwise and the reaction 
mixture was stirred at reflux for 5 h. The mixture was then cooled, and the volatiles removed under 
reduced pressure. Addition of a 10% aqueous NaOH solution (10 mL) was followed by extraction with 
Et2O (3 x 15 mL). The organic layers were then washed with brine and dried on anhydrous MgSO4, 
followed by removal of all volatiles under reduced pressure. This afforded an oily material which was 
subjected to column chromatography on silica gel (hexane-EtOAc mixtures) to yield the desired O-
allylated derivative. Yields were in the range between 50 and 85%. 
Conditions for Claisen rearrangements (28) 
A mixture of the appropriate O-allylated derivative (4 mmol) in dry hexane (40 mL) was treated 
dropwise under N2 with a 1M solution of Et2AlCl in dry hexane (8 mL for compounds having one O-
allyl group and 16 mL for compounds having two O-allyl groups). The mixture was then stirred at 
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room temperature until consumption of the starting materials (ca. 2 h, TLC monitoring). The mixture 
was then cooled in an ice bath, followed by slow dropwise addition of a 2M aqueous HCl solution (40 
mL). The mixture was poured into a separation funnel, and the organic phase was separated from the 
aqueous layer, which then was additionally extracted with EtOAc (4 x 15 mL). The combined organic 
layers were washed with brine, desiccated over anhydrous Na2SO4, followed by removal of all 
volatiles under reduced pressure. This afforded an oily material which was subjected to column 
chromatography on silica gel (hexane-EtOAc mixtures) to yield the desired C-allyl derivative. Yields 
were in the range between 30 and 60%. Crystallization of the solid products purified by means of 
column chromatography was performed using methanol. 
Physical data of individual compounds are given in the Supporting Information section. 
Biology 
Cell culture 
Cell culture media were purchased from Gibco (Grand Island, NY, USA). Fetal bovine serum 
(FBS) was a product of Harlan-Seralab (Belton, U.K.). Supplements and other chemicals not listed in 
this section were obtained from Sigma Chemicals Co. (St. Louis, Mo., USA). Plastics for cell culture 
were supplied by Thermo ScientificTM BioLite. All tested compounds were dissolved in DMSO at a 
concentration of 10 mg/mL and stored at –20ºC until use. 
Cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing glucose 
(1 g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 µg/mL) and amphotericin B (1.25 
µg/mL), supplemented with 10% FBS. 
Cytotoxicity assays 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Co., St. 
Louis, MO) dye reduction assay in 96-well microplates was used, as previously described (29). Some 5 
x 103 cells of HT-29, MCF-7 or HEK-293 cells in a total volume of 100 µL of their respective growth 
media were incubated with serial dilutions of the tested compounds. After 3 days of incubation (37 C, 
5% CO2 in a humid atmosphere), 10 µl of MTT (5 mg/ml in PBS) were added to each well and the 
plate was incubated for further 4 h (37 C). The resulting formazan was dissolved in 150 µL of 0.04 N 
HCl/2-propanol and read at 550 nm. All determinations were carried out in triplicate. 
ELISA analysis 
HT-29 cells at 70–80% confluence were collected after serum starvation for 24 h. Cells were 
incubated at the concentrations showed in Table 2 of the corresponding drugs in DMSO for 72 h (Fig. 
3). Culture supernatants were collected and VEGF secreted by HT-29 cells was determined using 
Invitrogen Human Vascular Endothelial Growth Factor ELISA Kit according to the manufacturer’s 
instructions. 
RT-qPCR analysis 
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HT-29 cells at 70–80% confluence were collected after serum starvation for 24 h. Cells were 
incubated at the concentrations showed in Table 2 of the corresponding drugs in DMSO for 48 h. Cells 
were collected and the total cellular RNA from HT-29 cells was isolated using Ambion RNA 
extraction Kit according to the manufacturer’s instructions. The cDNA was synthesized by MMLV-RT 
with 1-21 g of extracted RNA and oligo(dT)15 according to the manufacturer’s instructions. 
Amplification of the genes was performed by use of a StepOnePlus™ thermalcycler. Fast TaqMan 
Gene Expression Master Mix containing the appropriate buffer for the amplification conditions, 
dNTPs, thermostable DNA polymerase enzyme and a passive reference probe was used. Each of the 
genes were amplified using predesigned primers by Life Technologies TaqMan® Gene Expression 
Assays, Hs99999903-m1 (-actin), Hs00900055-m1 (VEGF), Hs00972646-m1 (hTERT) and 
Hs00153408-m1 (c-Myc). 
Statistical analysis 
Data are expressed as the mean ± SEM. Statistical analyses were done using Microsoft Excel and 
GraphPad Prism®. Differences between means were determined using one-way ANOVA with 
Dunnett's Multiple Comparison Test, and considered to be statistically significant at ≤0.05. 
 
Results and Discussion 
Cytotoxicity of the biphenyl derivatives 
The cytotoxic ability of compounds 1-36 was measured by means of their IC50 values towards the 
tumoral cell lines HT-29 and MCF-7 and towards the non-tumoral cell line HEK-293 (see Table 1). 
We have also evaluated the therapeutic safety margin of each compound as expressed by means of the 
and coefficients. These are obtained by dividing the IC50 value of each compound for the 
nontumoral HEK-293 line by those for the HT-29  and the MCF-7  tumoral cell line, 
respectively. The higher the value of either coefficient, the higher the therapeutic safety margin for the 
corresponding compound. 
The observed IC50 values are in the low to medium micromolar range. In general terms, these 
biphenyl derivatives exhibit the same cytotoxicity range in the HT-29 line as in the MCF-7 line. 
Compounds 3, 6 and 36 showed comparable or better IC50 values than honokiol towards the HT-29 cell 
line and, in addition, exhibited a markedly higher therapeutic margin than honokiol ( > 7). 
Compounds 4, 9, 15 and 16 exhibited better IC50 values than honokiol towards the MCF-7 cell line 
even though only 4 and 15 exhibited a higher therapeutic margin than honokiol ( > 3). 
Thirteen compounds (3, 6, 10, 12, 13, 15, 16, 17, 20, 22, 25, 28 and 36) were selected for further 
biological evaluations. The selection was made on the basis of products showing either comparatively 
low IC50 values (high cytotoxicity) or else  > 1 (good safety margin). 
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Table 1. IC50 values (µM) and selectivity coefficients for biphenyls 1-36.a 
Compound HEK-293 HT-29 MCF-7 * ** 
Honokiol 35 ± 7 25 ± 3 18.2 ± 0.5 1.5 1.9 
1 320 ± 30 227 ± 24 247 ± 24 1.4 1.3 
2 67 ± 6 101 ± 13 80.0 ± 0.9 0.7 0.8 
3 258 ± 5 27 ± 12 242 ± 4 9.7 1.1 
4 49 ± 5 208 ± 14 14 ± 4 0.2 3.6 
5 70 ± 30 210 ± 30 109 ± 15 0.3 0.7 
6 >100 11 ± 3 110 ± 14 >9 1 
7 104 ± 12 232 ± 22 230 ± 30 0.4 0.5 
8 140 ± 30 >100 230 ± 50 >1.4 0.6 
9 21 ± 5 69.5 ± 0.7 18 ± 4 0.3 1.2 
10 110 ± 9 56.0 ± 0.7 228 ± 13 2.0 0.5 
11 31 ± 6 180 ± 10 214 ± 10 0.2 0.1 
12 >100 70 ± 40 97 ± 5 >1.5 >1 
13 120 ± 40 70 ± 30 210 ± 3 1.6 0.6 
14 60 ± 30 219 ± 13 52.9 ± 2.1 0.3 1.2 
15 26 ± 5 38 ± 12 2.9 ± 0.14 0.7 8.7 
16 4.5 ± 2.3 32 ± 10 6.5 ± 2.2 0.1 1.1 
17 53 ± 13 44 ± 6 130 ± 40 1.2 0.4 
18 48 ± 3 >100 187 ± 14 0.5 0.3 
19 240 ± 11 290 ± 40 230 ± 50 0.8 1.0 
20 138 ± 14 120 ± 30 123 ± 5 1.2 1.1 
21 85 ± 10 105 ± 11 66 ± 6 0.8 1.3 
22 56 ± 18 60 ± 30 46.4 ± 0.6 0.9 1.2 
23 131 ± 13 175 ± 18 129 ± 13 0.7 1.0 
24 81 ± 3 >100 176 ± 23 0.8 0.5 
25 93 ± 4 79 ± 23 56 ± 13 1.2 1.7 
26 189 ± 9 >100 182 ± 7 1 1.1 
27 320 ± 70 23 ± 3 350 ± 30 0.6 0.7 
28 121 ± 19 69 ± 8 107 ± 12 1.7 1.1 
29 57 ± 3 50 ± 10 88 ± 14 0.3 0.3 
30 170 ± 40 147.7 ± 2.1 282 ± 20 0.4 0.7 
31 271 ± 8 290 ± 30 530 ± 40 0.5 0.7 
32 260 ± 30 270 ± 30 150 ± 40 0.9 0.6 
33 270 ± 30 280 ± 40 239 ± 6 0.1 0.2 
34 >100 209 ± 7 235 ± 3 0.2 0.2 
35 292 ± 10 240 ± 50 303 ± 9 0.1 0.5 
36 130 ± 30 19 ± 9 190 ± 30 7.1 0.7 
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aValues are the average ( s.d.) of three different measurements performed as described in 
the Experimental Section. b = IC50 (HEK-293) / IC50 (HT-29). c = IC50 (HEK-293) / IC50 
(MCF-7). Values of  and  have been rounded off to a decimal figure. 
 
Table 2. Concentrations for testing selected compounds. 
Concentration Biphenyl derivatives 
10 M 6, 36 
20 M Honokiol, 3, 16, 17 
40 M 10, 12, 13, 15, 22, 25 
60 M 28 
90 M 20 
  
 
Effect of biphenyl derivatives on VEGFA protein secretion and VEGF gene inhibition into HT-29 
The influence of the synthetic biphenyl derivatives on the secretion of the VEGFA protein and the 
expression of the VEGF gene was performed on the HT-29 line. The thirteen aforementioned 
compounds were tested at concentrations that were close to their respective IC50 values in the HT-29 
line (see Table 2). 
The amount of VEGFA protein was first determined by means of the ELISA procedure (30), as 
described in the Methods and Materials Section. Figure 3 shows the percentage of VEGFA secreted to 
the culture medium after 72 h of incubation in the presence of each of the selected compounds at 
concentrations showed in Table 2. The values observed when cells were treated only with DMSO were 
used as the control (standardized to 100%). 
Most of the studied derivatives showed an ability to diminish the secretion of VEGFA (Fig. 3) (31). 
Compound 16 showed an activity (59%) similar to that of honokiol at the same concentration whereas 
36 showed a 61% decrease in VEGFA secretion at half the concentration of honokiol. The strongest 
effect was observed with compounds 25 and 28, which were able to lower VEGFA protein secretion to 
40% and 47% of the control value, respectively, an effect stronger than that observed for honokiol 
(55%). However, it should also be noted that 25 and 28 were acting at a concentration twice and three 
times, respectively, higher than that of the natural product. 
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Figure 3. VEGFA protein secretion from HT-29 cells determined by means of the ELISA procedure. 
At least three measurements were performed in each case. Bars represent mean values of VEGFA 
secretion (percentage values related to control) and error bars indicate standard errors of the mean. The 
statistical analysis was evaluated using one-way ANOVA with Dunnett's Multiple Comparison Test (P 
< 0.001). 
In order to find out whether the selected biphenyl derivatives were able to downregulate the 
secretion of VEGFA protein by means of a mechanism based on interference at the transcriptional 
level, we tested the ability of the compounds to inhibit the expression of the VEGFA gene. In this case, 
HT-29 cells were incubated for 48 h with the selected derivatives at the concentrations shown in Table 
2, as well as with DMSO as the control test. The real time quantitative PCR (RT-qPCR) methodology 
(32) was then used as described in the Experimental Section to determine the percentage of VEGFA 
gene expression related to the control value. The results are shown in Figure 4. 
Seven of the thirteen studied synthetic derivatives showed an ability to diminish the expression of 
VEGFA gene to a noticeable degree (< 50% of the control value, with honokiol showing a 38% value). 
The most active compound was 6, which inhibited gene expression to 16% of the control value and at 
the lowest concentration of all of the tested compounds (half the concentration of honokiol). At the 
same concentration as the natural product, biphenyl derivatives 16 and 17 were able to decrease the 
expression of the VEGFA gene to less than 40% of the control value. Finally, compounds 12, 15 and 
22 lowered the expression of the VEGFA to 23, 24 % and 35%, respectively, of the control value, even 
though at a concentration twice higher than for honokiol. We can observe that most of these 
compounds display one allyloxy group at one at least of the two aromatic rings and the ortho position 
is usually not occupied. Furthermore, the most frequent substitution patterns for the oxygen atoms in 
these structures are meta-meta, meta-para and para-para. 
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Figure 4. Expression percentage of the VEGFA gene after 48 h of incubation of HT-29 cells 
determined by means of the RT-qPCR methodology. At least three measurements were performed in 
each case. Error bars indicate standard errors of the mean. The statistical analysis was evaluated using 
one-way ANOVA with Dunnett's Multiple Comparison Test (P < 0.001). 
It is worth mentioning here that the results discussed above do not show a good correlation 
between the VEGFA amount excreted to the medium and the degree of gene expression. This suggests 
that these compounds exert the control of VEGFA production at a phase different from that of gene 
transcription (33). 
Effect of biphenyl derivatives on the inhibition of the hTERT and c-Myc genes 
In order to determine whether the studied compounds were able to downregulate the expression of 
the hTERT and c-Myc genes, we have performed an RT-qPCR analysis on HT-29 tumoral cells. The 
cells were incubated for 48 h in the presence of DMSO (control) and the selected compounds (see 
Table 2). Figures 5 and 6 show the results observed for the expression of the hTERT and c-Myc genes, 
respectively. 
 
Figure 5. Expression percentage of the hTERT gene after 48 h of incubation. At least three 
measurements were performed in each case. Error bars indicate standard errors of the mean. The 
statistical analysis was evaluated using one-way ANOVA with Dunnett's Multiple Comparison Test (P 
< 0.001). 
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Figure 6. Expression percentage of the c-Myc gene after 48 h of incubation. At least three 
measurements were performed in each case. Error bars indicate standard errors of the mean. The 
statistical analysis was evaluated using one-way ANOVA with Dunnett's Multiple Comparison Test (P 
< 0.001). 
Honokiol and several of the synthetic biphenyl derivatives were able to inhibiting hTERT gene 
expression to levels below 50% of the control (45% for honokiol). Again, compound 6 and 36 deserve 
mention as they were able to lower hTERT gene expression to 34 % and 42%, respectively, of the 
control and at concentration one half that of the natural product (Fig. 5). Compounds 12 and 25 also 
diminished the expression of the gene to about 25% of the control value although at a concentration 
twice higher than that of honokiol. In this case, the most frequent substitution patterns for the oxygen 
atoms in the most active derivatives are meta-meta or meta-para. 
As regards the downregulation of the expression of the c-Myc gene (Fig. 6), compounds 13, 15, 16, 
22, 25 and 36 were able to diminish the expression of this gene to levels below 45% (the value for 
honokiol) of the control value. As above, compound 36 is also noteworthy as it caused a decrease of 
gene expression to 36 % of the control at half the concentration of honokiol. Compounds 15 and 25 
were also quite active, with gene expression reduced to 13% and 7%, respectively, of the control value, 
but at a concentration twice than that of honokiol. Another compound that showed a noticeable activity 
was 16, which lowered gene expression to 23% of the control at the same concentration as the natural 
product. Thus, the most frequent oxygen substitution patterns in this case are para-para or meta-para. 
Conclusions 
Thirty-six biphenyl derivatives structurally related to honokiol have been synthesized and 
biologically evaluated. All of them bear either O- or C-allyl groups. 
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IC50 values were first determined for all these biphenyl derivatives towards the HT-29, MCF-7 and 
HEK-293 cell lines. Some of these derivatives exhibited comparable or lower IC50 values than 
honokiol towards the HT-29 cell line or else higher therapeutic margin ( values) than the natural 
product. 
Thirteen of the derivatives (3, 6, 10, 12, 13, 15, 16, 17, 20, 22, 25, 28 and 36) were then selected 
for further biological evaluation on the basis of showing either comparatively low IC50 values or else  
> 1 (good safety margin). These derivatives were specifically evaluated for their ability to inhibit the 
secretion of the VEGFA protein and to inhibit the expression of the VEGFA, hTERT and c-Myc genes. 
We observed that, in general, the most active derivatives in these particular types of biological 
properties exhibited in many cases substitution patterns meta-meta or meta-para in their oxygen atoms. 
Table 3 summarizes the results obtained for compounds that showed the highest activity in 
simultaneously inhibiting the VEGFA protein secretion and the expression of the VEGFA, hTERT and 
c-Myc genes. All these derivatives exhibit two oxygen functions (OH or OR) and also two allyl units, 
either of the C-allyl or the O-allyl type. 
Table 3. Compounds with the highest activity in simultaneously inhibiting the VEGFA protein 
secretion and the expression of the VEGFA, hTERT and c-Myc genes. 
Biological 
activity 
IC50 (M) 
HT-29 
25 11 38 79 19 
 1.5 >9 0.7 1.2 7.1 
% VEGFA 
secretion 
55 76 58 40 61 
% VEGFA 
gene expr. 
36 16 24 42 55 
% hTERT 
gene expr. 
45 34 45 25 42 
% c-Myc 
gene expr. 
45 58 13 7 36 
 
Compound 6 turns out to be a very promising derivative as a potential anticancer agent because it 
is able to simultaneously diminish the expression of all three targeted genes at a concentration in the 
low micromolar range (half the concentration used for honokiol). In addition, 6 exhibits the highest 
therapeutic margin of all the tested derivatives, honokiol included, and has no free hydroxyl groups. 
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This feature could be advantageous because, as it is not able to form glucuronide conjugates, it may 
exhibit a lower metabolization rate. Compounds of this type therefore deserve to be the object of 
further pharmacological investigation. 
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